{"id":"W4318925936","doi":"10.1158/1078-0432.ccr-22-3484","title":"Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in <i>EGFR</i> -Mutant Lung Adenocarcinomas","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Canadian Institutes of Health Research; National Cancer Institute; Royal College of Physicians and Surgeons of Canada; National Institutes of Health; Memorial Sloan-Kettering Cancer Center; Pfizer","keywords":"Osimertinib; T790M; Medicine; Lung cancer; Combination therapy; Oncology; Gefitinib; Acquired resistance; Internal medicine; Epidermal growth factor receptor; Regimen; Afatinib; Pharmacology; Cancer; Erlotinib","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000907708,0.0006888214,0.0005686089,0.0001762542,0.0002697902,0.0006714455,0.0005198818,0.001102731,0.005807695],"category_scores_gemma":[0.000702991,0.0001486469,0.0004125835,0.0002099846,0.0002436964,0.0003144967,0.0001611584,0.001017943,0.001264636],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005961361,"about_ca_system_score_gemma":0.0007593822,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002821067,"about_ca_topic_score_gemma":0.000487796,"domain_scores_codex":[0.9996438,0.0001027284,0.00004366087,0.00007073004,0.00008112386,0.00005791052],"domain_scores_gemma":[0.9993625,0.0001526522,0.0001250067,0.00003585357,0.0001398399,0.0001840996],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.02426139,0.003557583,0.01135621,0.004277365,0.0007998248,0.007649182,0.0002219358,0.001186324,0.1064012,0.001140854,0.3259536,0.5131947],"study_design_scores_gemma":[0.01545519,0.0836227,0.04223219,0.0005704678,0.002140444,0.03369574,0.0002587414,0.003815357,0.1772246,0.0009494622,0.6399298,0.0001053654],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.6929835,0.1435961,0.01119695,0.04355397,0.03091897,0.002835712,0.00547064,0.00139992,0.06804423],"genre_scores_gemma":[0.8439295,0.04767488,0.005866783,0.01086281,0.03751105,0.0007602386,0.004542946,0.0001539203,0.04869786],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005807695,"threshold_uncertainty_score":0.01942867,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1060353507834089,"score_gpt":0.498558414973884,"score_spread":0.3925230641904751,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}